See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Stock Markets
Social Media
Tariffs
UK Economy
Taxes
Soccer
Donald Trump
Education
Senate
Artificial Intelligence
Published • loading... • Updated

FDA OKs Cabozantinib for Pancreatic Neuroendocrine Tumors

Summary by Medscape
Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo. Medscape Medical News

11 Articles

All
Left
Center
Right
rarecancernews.comrarecancernews.com

Cabometyx wins FDA approval to treat certain pancreatic cancers

The U.S. Food and Drug Administration (FDA) has granted its approval to the oral medication Cabometyx (cabozantinib) as a treatment for certain types of pancreatic cancer. The approval specifically covers the use of Cabometyx for patients ages 12 and older who have previously treated, unresectable — meaning the cancer cannot be surgically removed — locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors. The therapy …

Read Full Article
Stemwell Science NewsStemwell Science News

Curcumin Ameliorates Cerulein‑Induced Chronic Pancreatitis through Nrf‑2/HO‑1 Signaling

Researchers investigated whether curcumin improved cerulein‑induced chronic pancreatitis fibrosis in a mouse model and pancreatic stellate cells. [Molecular Medicine Reports] Abstract

Read Full Article
MedscapeMedscape
Reposted by
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News

FDA OKs Cabozantinib for Pancreatic Neuroendocrine Tumors

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo. Medscape Medical News

·United States
Read Full Article
Endpoints NewsEndpoints News

Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors

The FDA has approved Exelixis' cancer drug Cabometyx to treat advanced neuroendocrine tumors inside and outside of the pancreas, marking two new indications for the company’s primary source of revenue. The new label includes adults ...

Read Full Article
csimarket.comcsimarket.com

#Exelixis Secures FDA Approval for CABOMETYX A Step Forward for Neuroendocrine Tumor Treatment Amid Market Dynamics

In a significant advancement in cancer treatment, Exelixis, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX (cabozantinib) for patients aged 12 years and older with previously treated advanced neuroendocrine tumors (NET). This approval marks a notable milestone in the management of well-differentiated pancreatic neuroendocrine tumors (pNET), as it provides new hope for patients with unresectable, locall…

Read Full Article
Managed Healthcare ExecutiveManaged Healthcare Executive

FDA Approves Cabometyx to Treat Advanced Pancreatic Cancer

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Neuroendocrine Cancer UK broke the news in on Wednesday, March 26, 2025.
Sources are mostly out of (0)

Similar News Topics

Medical

Medical

United States

United States

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal